Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six-month, randomized, placebo-controlled, double-blind clinical trial.
Tuccinardi D, Farr OM, Upadhyay J, Oussaada SM, Mathew H, Paschou SA, Perakakis N, Koniaris A, Kelesidis T, Mantzoros CS. Tuccinardi D, et al. Among authors: farr om. Diabetes Obes Metab. 2019 Jun;21(6):1487-1492. doi: 10.1111/dom.13655. Epub 2019 Mar 18. Diabetes Obes Metab. 2019. PMID: 30724455 Free PMC article. Clinical Trial.
Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical Trial.
Farr OM, Upadhyay J, Gavrieli A, Camp M, Spyrou N, Kaye H, Mathew H, Vamvini M, Koniaris A, Kilim H, Srnka A, Migdal A, Mantzoros CS. Farr OM, et al. Diabetes. 2016 Oct;65(10):2943-53. doi: 10.2337/db16-0635. Epub 2016 Jul 6. Diabetes. 2016. PMID: 27385157 Free PMC article. Clinical Trial.
Mechanisms underlying the cardiometabolic protective effect of walnut consumption in obese people: A cross-over, randomized, double-blind, controlled inpatient physiology study.
Tuccinardi D, Farr OM, Upadhyay J, Oussaada SM, Klapa MI, Candela M, Rampelli S, Lehoux S, Lázaro I, Sala-Vila A, Brigidi P, Cummings RD, Mantzoros CS. Tuccinardi D, et al. Among authors: farr om. Diabetes Obes Metab. 2019 Sep;21(9):2086-2095. doi: 10.1111/dom.13773. Epub 2019 Jul 2. Diabetes Obes Metab. 2019. PMID: 31087608 Free PMC article. Clinical Trial.
Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies.
Farr OM, Upadhyay J, Rutagengwa C, DiPrisco B, Ranta Z, Adra A, Bapatla N, Douglas VP, Douglas KAA, Nolen-Doerr E, Mathew H, Mantzoros CS. Farr OM, et al. Diabetes Obes Metab. 2019 Nov;21(11):2459-2464. doi: 10.1111/dom.13827. Epub 2019 Aug 8. Diabetes Obes Metab. 2019. PMID: 31282006 Free PMC article. Clinical Trial.
Fasting oxyntomodulin, glicentin, and gastric inhibitory polypeptide levels are associated with activation of reward- and attention-related brain centres in response to visual food cues in adults with obesity: A cross-sectional functional MRI study.
Perakakis N, Farr OM, Mantzoros CS. Perakakis N, et al. Among authors: farr om. Diabetes Obes Metab. 2021 May;23(5):1202-1207. doi: 10.1111/dom.14315. Epub 2021 Jan 22. Diabetes Obes Metab. 2021. PMID: 33417264
Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial.
Peradze N, Farr OM, Perakakis N, Lázaro I, Sala-Vila A, Mantzoros CS. Peradze N, et al. Among authors: farr om. Cardiovasc Diabetol. 2019 Oct 31;18(1):141. doi: 10.1186/s12933-019-0945-7. Cardiovasc Diabetol. 2019. PMID: 31672146 Free PMC article. Clinical Trial.
55 results